Molecular Pathways of Neurodegeneration in Parkinson's Disease

Research output: Contribution to journalArticle

Abstract

Parkinson's disease (PD) is a complex disorder with many different causes, yet they may intersect in common pathways, raising the possibility that neuroprotective agents may have broad applicability in the treatment of PD. Current evidence suggests that mitochondrial complex I inhibition may be the central cause of sporadic PD and that derangements in complex I cause α-synuclein aggregation, which contributes to the demise of dopamine neurons. Accumulation and aggregation of α-synuclein may further contribute to the death of dopamine neurons through impairments in protein handling and detoxification. Dysfunction of parkin (a ubiquitin E3 ligase) and DJ-1 could contribute to these deficits. Strategies aimed at restoring complex I activity, reducing oxidative stress and α-synuclein aggregation, and enhancing protein degradation may hold particular promise as powerful neuroprotective agents in the treatment of PD.

Original languageEnglish (US)
Pages (from-to)819-822
Number of pages4
JournalScience
Volume302
Issue number5646
DOIs
StatePublished - Oct 31 2003

Fingerprint

Synucleins
Parkinson Disease
Dopaminergic Neurons
Neuroprotective Agents
Ubiquitin-Protein Ligases
Proteolysis
Oxidative Stress
Proteins

ASJC Scopus subject areas

  • General

Cite this

Molecular Pathways of Neurodegeneration in Parkinson's Disease. / Dawson, Ted M; Dawson, Valina.

In: Science, Vol. 302, No. 5646, 31.10.2003, p. 819-822.

Research output: Contribution to journalArticle

@article{ffc29dd9eb21446ea932e5578ad981b4,
title = "Molecular Pathways of Neurodegeneration in Parkinson's Disease",
abstract = "Parkinson's disease (PD) is a complex disorder with many different causes, yet they may intersect in common pathways, raising the possibility that neuroprotective agents may have broad applicability in the treatment of PD. Current evidence suggests that mitochondrial complex I inhibition may be the central cause of sporadic PD and that derangements in complex I cause α-synuclein aggregation, which contributes to the demise of dopamine neurons. Accumulation and aggregation of α-synuclein may further contribute to the death of dopamine neurons through impairments in protein handling and detoxification. Dysfunction of parkin (a ubiquitin E3 ligase) and DJ-1 could contribute to these deficits. Strategies aimed at restoring complex I activity, reducing oxidative stress and α-synuclein aggregation, and enhancing protein degradation may hold particular promise as powerful neuroprotective agents in the treatment of PD.",
author = "Dawson, {Ted M} and Valina Dawson",
year = "2003",
month = "10",
day = "31",
doi = "10.1126/science.1087753",
language = "English (US)",
volume = "302",
pages = "819--822",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "5646",

}

TY - JOUR

T1 - Molecular Pathways of Neurodegeneration in Parkinson's Disease

AU - Dawson, Ted M

AU - Dawson, Valina

PY - 2003/10/31

Y1 - 2003/10/31

N2 - Parkinson's disease (PD) is a complex disorder with many different causes, yet they may intersect in common pathways, raising the possibility that neuroprotective agents may have broad applicability in the treatment of PD. Current evidence suggests that mitochondrial complex I inhibition may be the central cause of sporadic PD and that derangements in complex I cause α-synuclein aggregation, which contributes to the demise of dopamine neurons. Accumulation and aggregation of α-synuclein may further contribute to the death of dopamine neurons through impairments in protein handling and detoxification. Dysfunction of parkin (a ubiquitin E3 ligase) and DJ-1 could contribute to these deficits. Strategies aimed at restoring complex I activity, reducing oxidative stress and α-synuclein aggregation, and enhancing protein degradation may hold particular promise as powerful neuroprotective agents in the treatment of PD.

AB - Parkinson's disease (PD) is a complex disorder with many different causes, yet they may intersect in common pathways, raising the possibility that neuroprotective agents may have broad applicability in the treatment of PD. Current evidence suggests that mitochondrial complex I inhibition may be the central cause of sporadic PD and that derangements in complex I cause α-synuclein aggregation, which contributes to the demise of dopamine neurons. Accumulation and aggregation of α-synuclein may further contribute to the death of dopamine neurons through impairments in protein handling and detoxification. Dysfunction of parkin (a ubiquitin E3 ligase) and DJ-1 could contribute to these deficits. Strategies aimed at restoring complex I activity, reducing oxidative stress and α-synuclein aggregation, and enhancing protein degradation may hold particular promise as powerful neuroprotective agents in the treatment of PD.

UR - http://www.scopus.com/inward/record.url?scp=0242363670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242363670&partnerID=8YFLogxK

U2 - 10.1126/science.1087753

DO - 10.1126/science.1087753

M3 - Article

VL - 302

SP - 819

EP - 822

JO - Science

JF - Science

SN - 0036-8075

IS - 5646

ER -